CorMedix Historical Cash Flow
| CRMD Stock | USD 8.57 0.30 3.38% |
Analysis of CorMedix cash flow over time is an excellent tool to project CorMedix future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 58.7 M or End Period Cash Flow of 46 M as it is a great indicator of CorMedix ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining CorMedix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CorMedix is a good buy for the upcoming year.
CorMedix |
About CorMedix Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in CorMedix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which CorMedix's non-liquid assets can be easily converted into cash.
CorMedix Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in CorMedix financial statement analysis. It represents the amount of money remaining after all of CorMedix operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from CorMedix's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into CorMedix current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.At present, CorMedix's End Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 5.8 M, whereas Change In Cash is forecasted to decline to about 426 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 7.1M | 124.4K | 134.8K | 128.1K | Depreciation | 61.9K | 84.6K | 70.8K | 46.3K |
CorMedix cash flow statement Correlations
Click cells to compare fundamentals
CorMedix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CorMedix cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 36.6K | 112.6K | 1.4M | 219.4K | 327.3K | 169.8K | |
| Total Cash From Financing Activities | 25.8M | 40.1M | 41.8M | 17.9M | 55.9M | 58.7M | |
| End Period Cash Flow | 16.5M | 42.1M | 53.6M | 43.4M | 43.8M | 46.0M | |
| Change In Cash | (1.3M) | 25.6M | 11.5M | (10.2M) | 448.4K | 426.0K | |
| Stock Based Compensation | 2.4M | 2.5M | 5.0M | 4.1M | 5.5M | 5.8M | |
| Free Cash Flow | (15.1M) | (22.1M) | (22.6M) | (24.6M) | (38.7M) | (36.8M) | |
| Change In Working Capital | (1.9M) | (2.6M) | 1.8M | 1.1M | 2.2M | 2.3M | |
| Begin Period Cash Flow | 17.8M | 16.5M | 42.1M | 53.6M | 43.4M | 45.5M | |
| Other Cashflows From Financing Activities | 10.6M | 411.8K | 301.9K | 128.6K | 89.3K | 84.8K | |
| Depreciation | 73.3K | 128.0K | 61.9K | 84.6K | 70.8K | 46.3K | |
| Other Non Cash Items | 1.4M | 60.0K | 7.1M | 124.4K | 134.8K | 128.1K | |
| Total Cash From Operating Activities | (15.1M) | (22.0M) | (21.2M) | (24.4M) | (38.4M) | (36.5M) | |
| Net Income | (16.4M) | (22.0M) | (28.2M) | (29.7M) | (46.3M) | (44.0M) | |
| Change To Liabilities | (1.9M) | 101.1K | 1.1M | (6.6K) | (5.9K) | (5.6K) | |
| Sale Purchase Of Stock | 26.0M | 40.1M | 41.8M | (198.4K) | (228.2K) | (216.8K) | |
| Change To Inventory | 59.3K | 149.6K | 145.5K | 3.0K | (2.1M) | (2.0M) | |
| Total Cashflows From Investing Activities | (12.0M) | 7.4M | (9.1M) | (3.7M) | (3.3M) | (3.2M) | |
| Cash And Cash Equivalents Changes | 7.2M | (1.3M) | 25.6M | 11.5M | 13.2M | 13.8M | |
| Cash Flows Other Operating | 23.2K | 394.5K | (2.9M) | 767.0K | 690.3K | 606.6K | |
| Change To Account Receivables | (47.6K) | 52.0K | 10.6K | (3.1K) | (44.1K) | 42.1K | |
| Other Cashflows From Investing Activities | (12.0M) | 7.5M | (9.1M) | (3.7M) | (3.3M) | (3.2M) | |
| Change To Netincome | 2.5M | 2.6M | 5.0M | 4.2M | 4.8M | 3.4M | |
| Change Receivables | 52.0K | 10.6K | (3.1K) | (44.1K) | (50.7K) | (48.2K) | |
| Exchange Rate Changes | (7.9K) | (2.0K) | 13.2K | (12.9K) | (14.9K) | (15.6K) | |
| Investments | (12.0M) | 7.5M | (7.7M) | (3.7M) | (17.1M) | (16.2M) | |
| Change To Operating Activities | (430.7K) | (2.9M) | 651.9K | 1.0M | 925.0K | 971.3K | |
| Issuance Of Capital Stock | 15.2M | 39.7M | 41.5M | 17.8M | 55.8M | 35.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.